CHINESE

幼兒哮喘治療計劃

0-5歳

	Patient Name:	
	Medical Record #:	
	DOB:	
垺	真 表人:	日期:
	使用次數	其他説明 (如間隔器/面罩、噴霧器)
	每天次數 每天使用!	
	每天次數 每天使用!	
	每天次數 每天使用!	
	———— 每天次數 每天使用!	
	使用次數	 其他説明
		注: 如果需要經常使用

本藥(______每周次數),

綠色區

孩子感到**舒適**,即 使在活躍的活動中 也沒有哮喘癥狀。

快速解喘藥物



使用劑量

使用劑量

孩子感到**不舒適**,並有以下的 哮喘癥狀:

• 咳嗽

醫療保健機構名稱:

醫療保健機構電話:

病癥控制藥物

(每天使用以保持健康)

- 喘息
- 流鼻涕或有其他感冒癥狀
- 呼吸困難或加快
- 由於咳嗽和呼吸困難而無法入睡
- 比平時活動減少

責色區

鱼

顯示孩子呼吸有困難的癥狀可能包括: 難以餵食、 (打呼嚕、無力吸奶)、睡眠習慣變化、脾氣急躁並顯 疲憊,食慾不振。

孩子**感覺極壞!** 預警癥狀包括:

- 即使在使用黃色區的藥物之後,孩子的喘息、 咳嗽或呼吸困難仍持續或加劇。
- 孩子的呼吸非常困難並妨礙其行走、講話、進食或玩耍。
- 孩子發睏或沒有平時那麼警覺。

情況危急! 請立即求助!

葙	防每	天	的喽	喘癥	北
124	19J 13	\mathcal{I}	コンプチ	"IIII /IEX	ハハ

- 每天使用上述的控制藥物。
- 避免孩子接觸使哮喘惡化的東西。

儘在需要時使用

避免接觸抽煙的煙霧	,	要求吸煙者到戶外抽煙	c

生音	_	繼續估	田伝	工 的正	告唑	学兹协	n 173 ·

使用			

(include dose and frequency)

如果孩子不在**綠色區**並在一個小時之後仍有癥狀,那麼:

更多使用
(include dose and frequency)

	(include dose and frequency)	
□ 打電話		

危急癥狀!立即求助!

读帶孩子	去醫院或立	- 即打911	雷話!
严 下 1 人 1	ム四かみユ	ייט וניאט -	

□ 更多使用	
直到得到援助。	(include dose and frequency)

使用 _______(include dose and frequency)

- 請打911電話,如有以下情況: • 孩子頸部或肋骨的皮膚出現內陷;或
- 孩子的嘴唇和/或指甲變灰或發青;或
- 孩子沒有反應。

PROVIDER INSTRUCTIONS FOR ASTHMA ACTION PLAN (Children ages 0-5)

□ DETERMINE THE LEVEL OF ASTHMA SEVERITY (see Table 1)

FILL IN MEDICATIONS

Fill in medications appropriate to that level (see Table 1) and include instructions, such as "shake well before using", "use with spacer", and "rinse mouth after using'

ADDRESS ISSUES RELATED TO ASTHMA SEVERITY

These can include allergens, smoke, rhinitis, sinusitis, gastroesophageal reflux, sulfite sensitivity, medication interactions, and viral respiratory infections.

FILL IN AND REVIEW ACTION STEPS

Complete the recommendations for action in the different zones, and review the whole plan with the family so they are clear on how to adjust the medications, and when to call for help.

TABLE 1: Severity and medication chart (classification is based on meeting at least one criterion)

□ DISTRIBUTE COPIES OF THE PLAN

Give the top copy of the plan to the family, the next one to school, day care, caretaker, or other involved third party as appropriate, and file the last copy in the chart.

REVIEW ACTION PLAN REGULARLY (Step Up / Step Down Therapy)

considerations are met, the patient should "step up" to a higher classification of "step down" and be reclassified to a lower level of asthma severity and treatment. A patient frequently in the yellow or red zone should be assessed to make sure inhaler technique is correct, adherence is good, environmental factors are not interfering asthma severity and treatment. Be sure to fill out a new asthma action plan when A patient who is always in the green zone for some months may be a candidate to with treatment, and alternative diagnoses have been considered. changes in treatment are made.

	Severe Persistent	Moderate Persistent	Mild Persistent	Mild Intermittent
Symptoms/Day	Continual symptoms	Daily symptoms	> 2 days/week but < 1 time/day	≤ 2 days/week
Symptoms/Night	Frequent	> 1 night/week	> 2 nights/month	≤2 nights/month
Long Term	Preferred treatment: • Daily <u>high-dose</u> inhaled	Preferred treatment: • Daily <u>low-dose</u> inhaled corticosteroid and	Preferred treatment: • Daily low-dose inhaled corticosteroid	No daily medication needed.
Control ¹	corticosteroid AND	long-acting inhaled B_2 - agonist OR	(with nebulizer or MDI with holding chamber with or without face	
	• Long-acting inhaled B_2 - agonist	 Daily <u>medium-dose</u> inhaled corticosteroid Alternative treatment: 	mask or DPI) Alternative treatment:	
	AND, if needed:	 Daily low-dose inhaled corticosteroid and 	 Cromolyn (nebulizer is preferred or 	
	 Corticosteroid tablets or syrup long term (2 mg/kg/day, 	either leukotriene receptor antagonist or theophylline	MDI with holding chamber) OR	
	generally do not exceed 60 mg		 Leukotriene receptor antagonist 	
	per day). (Make repeated	If needed (particularly in patients with recurring		
	attempts to reduce systemic	severe exacerbations):	Note: Initiation of long-term controller	
	corticosteroids and maintain	Preferred treatment:	therapy should be considered if child has	
	control with high-dose inhaled	 Daily <u>medium-dose</u> inhaled corticosteroid and 	had more than three episodes of	
	corticosteroids.)	long-acting B_2 – agonist	wheezing in the past year that lasted more	
		Alternative treatment:	than one day and affected sleep and who	
		• Daily <u>medium-dose</u> inhaled corticosteroid and	have risk factors for the development of	
		etrier leukotrierie receptor arragoriist or theophylline	asthma."	
	Consultation With Asthma	Consultation With Asthma	Consider Consultation With	
	Specialist Recommended	Specialist Recommended	Asthma Specialist	
	Preferred treatment:	Preferred treatment:	Preferred treatment:	Preferred Treatment:
Quick Relief	 Inhaled short-acting B₂- agonist 	 Inhaled short-acting B₂ - agonist 	 Inhaled short-acting B₂ - agonist 	 Inhaled short-acting B₂-agonist
	Alternative treatment:	Alternative treatment:	Alternative treatment:	Alternative Treatment
	• Oral B ₂ - agonist	• Oral B ₂ - agonist	• Oral B ₂ - agonist	 Oral B₂ - agonist

1 For Infants and children use spacer or spacer AND MASK.

It is a state of the development of astima are parental history of astima, physician-diagnosed atopic dermatitis, or two of the following: physician-diagnosed altergic rhinitis, wheezing apart from colds, peripheral blood eosinophilia. With viral ratory for the development of astima are parental history as to 24 hours (longer with physician consult); in general no more than once every six weeks.

If patient has seasonal astima on a predictable basis, long-term anti-inflammatory therapy (inhaled corticosteroids, cromolyn) should be initiated prior to the anticipated onset of symptoms and continued through the season.

Inititive, a program of the Public Health Institute. This plan is based on the recommendations from the National Heart, Lung, and Blood Institute's, "Guidelines for the Diagnosis and Management of Asthma," NIH Publication No. 02-5075 (June 2002). The information contained herein is intended for the use and convenience of physicians and other medical personnel, and may not be appropriate for use in all circumstances. Decisions to adopt any particular recommendation must be made by qualified medical personnel in light of available resources and the circumstances presented by individual patients. No This Asthma Plan was developed by a committee facilitated by the Childhood Asthma Initiative, a program funded by the California Children and Families Commission, and the Regional Asthma Management and Prevention (RAMP) entity or individual involved in the funding or development of this plan makes any warranty guarantee, express or implied, of the quality, fitness, performance or results of use of the information or products described in the plan or the Guidelines. For additional information, please contact RAMP at (510)622-4438, https://www.rampasthma.org.